Commentary

Video

Dr Choueiri on the Phase 3 TiNivo-2 Study in Pretreated Advanced RCC

Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, Kidney Cancer Program, senior physician, Dana-Farber Cancer Institute, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, discusses the phase 3 TiNivo-2 study (NCT04987203) in pretreated advanced renal cell carcinoma (RCC).

TiNivo-2 is a randomized trial comparing tivozanib (Fotivda) plus nivolumab (Opdivo) vs tivozanib monotherapy in patients with RCC following disease progression on 1 or 2 prior lines of therapy, including an immune checkpoint inhibitor. The study is fully accrued, and findings are expected later this year; the results could potentially be practice altering if a benefit is observed with immune checkpoint inhibitor rechallenge, Choueiri says.

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Alberto Montero, MD, MBA, CPHQ
Thomas Westbrook, MD, assistant professor, Rush University Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Chad Tang, MD
Martin H. Voss, MD
Martin H. Voss, MD
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO